Skyrizi® (risankizumab-rzaa – AbbVie) is now the first and only specific interleukin-23 (IL23) inhibitor to receive FDA approval for treating moderately to severely active Crohn’s disease in adults.

• First FDA approved in 2019, Skyrizi is also indicated to treat active psoriatic arthritis and moderate to severe plaque psoriasis.
• The recommended starting dose for Crohn’s disease is 600mg administered by intravenous infusion at Weeks 0, 4, and 8 of treatment. Maintenance treatment begins at Week 12, with a recommended dose of 360mg administered by subcutaneous injection once every eight weeks.